Early viral load and CD4+ T cell count, but not percentage of CCR5+ or CXCR4+ CD4+ T cells, are associated with R5-to-X4 HIV type 1 virus evolution

AIDS Research and Human Retroviruses

Volumn 19, Issue 5, 2003, Pages 389-398

  Van Rij, Ronald P ^a   Hazenberg, Mette D ^a   Van Benthem, Birgit H B ^b   Otto, Sigrid A ^a   Prins, Maria ^b   Miedema, Frank ^a   Schuitemaker, Hanneke ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c Sanquin ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; VIRUS RNA;

ADULT; ARTICLE; CHRONOLOGY; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE; VIRUS LOAD; VIRUS MUTATION;

ADULT; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DISEASE PROGRESSION; EVOLUTION, MOLECULAR; FLOW CYTOMETRY; GIANT CELLS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, VIRAL; VIRAL LOAD;

EID: 0037845304     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203765551737     Document Type: Article

References (53)

1. Hoffman TL and Doms RW: Chemokines and coreceptors in HIV/SIV-host interactions. AIDS 1998;12:S17-S26.
2. Loetscher P, Moser B, and Baggiolini M: Chemokines and their receptors in lymphocyte traffick and HIV infection. Adv Immunol 2000;74:127-180.
3. Zhu T, Mo H, Wang N, et al.: Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993;261:1179-1181.
4. Van't Wout AB, Kootstra NA, Mulder-Kampinga GA, et al.: Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral and vertical transmission. J Clin Invest 1994;94:2060-2067.
5. Samson M, Libert F, Doranz BJ, et al.: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-725.
6. Liu R, Paxton WA, Choe S, et al.: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377.
7. + cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-688.
8. + T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1 infected individuals. J Virol 1993;67:1772-1777.
9. Scarlatti G, Tresoldi E, Björndal Å, et al.: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine mediated suppression. Nat Med 1997;3:1259-1265.
10. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
11. Koot M, Van Leeuwen R, De Goede REY, et al.: Conversion rate towards a syncytium inducing (SI) phenotype during different stages of HIV-1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999;179:254-258.
12. De Jong JJ, De Ronde A, Keulen W, Tersmette M, and Goudsmit J: Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992;66: 6777-6780.
13. Fouchier RAM, Groenink M, Kootstra NA, et al.: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-3187.
14. + T cell decline. Proc Natl Acad Sci USA 2000;97:1269-1274.
15. van Rij RP, Blaak H, Visser JA, et al.: Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. J Clin Invest 2000;160: 1039-1052.
16. Camerini D, Su HP, Gamez-Torre G, et al.: Human immunodeficiency virus type 1 pathogenesis in SCID-hu mice correlates with syncytium-inducing phenotype and viral replication. J Virol 2000;74:3196-3204.
17. Berkowitz RD, Alexander S, Bare C, et al.: CCR5- and CXCR4-utilizing strains of human immunodeficiency virus type 1 exhibit differential tropism and pathogenesis in vivo. J Virol 1998;72: 10108-10117.
18. Kuiken CL, De Jong J-J, Baan E, et al.: Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol 1992;66:4622-4627.
19. Oberlin E, Amara A, Bachelerie F, et al.: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line adapted HIV-1. Nature 1996;382:833-835.
20. Xiao H, Neuveut C, Tiffany HL, et al.: Selective CXCR4 antagonism by Tat: Implications for in vivo expansion of coreceptor usage by HIV-1. Proc Natl Acad Sci USA 2000;97:11466-11471.
21. Ghezzi S, Noonan DM, Grazia Aluigi M, et al.: Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat. Biochem Biophys Res Commun 2000;270:992-996.
22. Klein MR, Keet IPM, D'Amaro J, et al.: Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam Cohort of homosexual men. J Infect Dis 1994;169:1244-1249.
23. Nakayama EE, Hoshino Y, Xin X, et al.: Polymorphism in the interleukin-4 promotor affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. J Virol 2000;74:5452-5459.
24. van Rij RP, De Roda Husman AM, Brouwer M, et al.: Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. J Infect Dis 1998; 178:1806-1811.
25. Vicenzi E, Ghezzi S, Brambilla A, et al.: CCR2-64I polymorphism, syncytium-inducing human immunodeficiency virus strains and disease progression. J Infect Dis 2000;182:1578-1579.
26. D'Aquila RT, Sutton L, Savara A, et al.: CCR5/Dccr5 heterozygosity: A selective pressure for the syncytium-inducing human immunodeficiency virus type 1 phenotype. J Infect Dis 1998;177: 1549-1553.
27. Valentin A, Lu W, Rosati M, et al.: Dual effect of interleukin 4 on HIV-1 expression: Implications for viral phenotypic switch and disease progression. Proc Natl Acad Sci USA 1998;95:8886-8891.
28. Bleul CC, Farzan M, Choe H, et al.: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829-832.
29. + T cells. Science 1995;270:1811-1815.
30. Murakami T, Nakajima T, Koyanagi Y, et al.: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997;186:1389-1393.
31. Simmons G, Clapham PR, Picard L, et al.: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-279.
32. Donzella G, Schols D, Lin SW, et al.: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998;4:72-77.
33. Schols D, Struyf S, Van Damme J, et al.: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-1388.
34. Doranz BJ, Grovit-Ferbas K, Sharron MP, et al.: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997;186:1395-1400.
35. Michael NL and Moore JP: HIV-1 entry inhibitors: Evading the issue. Nat Med 1999;5:740-741.
36. Koot M, Vos AHV, Keet RPM, et al.: HIV-1 biological phenotype in long term infected individuals, evaluated with an MT-2 cocultivation assay. AIDS 1992;6:49-54.
37. De Roda Husman AM, Koot M, Cornelissen M, et al.: Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997;127:882-890.
38. Hazenberg MD, Otto SA, van Benthem BHB, et al.: Persistant immune activation in HIV-1 infection is associated with naive T cell depletion and progression to AIDS. AIDS 2003 (in press).
39. Bleul CC, Wu L, Hoxie JA, Springer TA, and Mackay CR: The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997;94:1925-1930.
40. Ostrowski MA, Justement SJ, Cantanzaro A, et al.: Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol 1998;161:3195-3201.
41. De Roda Husman AM, Blaak H, Brouwer M, and Schuitemaker H: CCR5 cell-surface expression in relation to CCR5 genotype and the clinical course of HIV-1 infection. J Immunol 1999;163: 4597-4603.
42. Blaak H, Ran LJ, Rientsma R, and Schuitemaker H: Susceptibility of in vitro stimulated PBMC to infection with NSI HIV-1 is associated with levels of CCR5 expression and β-chemokine production. Virology 2000;267:237-246.
43. Hazenberg MD, Cohen Stuart JWT, Otto SA, et al.: T cell division in human immunodeficiency virus (HIV-1)-infection is mainly due to immune activation: A longitudinal analysis in patients before and during highly active anti-retroviral therapy. Blood 2000;95:249-255.
44. Ioannidis JPA, Rosenberg P.S, Goldert JJ, et al.: Effects of CCR5-Delta 32, CCR2-641, and SDF-1 3′ A alleles on HIV-1 disease progression: An international meta-analysis of individual patient data. Ann Intern Med 2001;135:782-795.
45. + lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression. J Infect Dis 2001;183:1678-1681.
46. Meyer L, Magierowska M, Hubert J-B, et al.: Early protective effect of CCR5 Δ32 heterozygosity on HIV-1 disease progression: Relationship with viral load. AIDS 1997;11:F73-F78.
47. Schols D, Este JA, Cabrera C, and De Clercq E: T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1α contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol 1998;72:4032-4037.
48. Arakaki R, Tamamura H, Premanathan M, et al.: T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999;73:1719-1723.
49. De Vreese K, Kofler-Mongold V, Leutgeb C, et al.: The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J Virol 1996;70:689-696.
50. Aarons EJ, Beddows S, Willingham T, Wu L, and Koup RA: Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology 2001;287:382-390.
51. Kanbara K, Sato S, Tanuma J-I, et al.: Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134. AIDS Res Hum Retroviruses 2001;17: 615-622.
52. Trkola A, Kuhmann SE, Strizki JM, et al.: HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002;99:395-400.
53. Mosier DE, Picchio GR, Gulizia RJ, et al.: Highly potent RANTES analoques either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999;73:3544-3550.